血清Lipocalin-2、Ficolin-2与下肢动脉硬化闭塞症介入治疗后血管再狭窄的相关性研究  

The correlation between serum Lipocalin-2,Ficolin-2 and vascular restenosis after interventional treatment of lower extremity arteriosclerosis obliterans

作　　者：单绍银 赵刘兵 童垣皓 刘超[1] 张蔚然[1] 沈镜孚 韩志锋[1] Shan Shaoyin;Zhao Liubing;Tong Yuanhao;Liu Chao;Zhang Weiran;Shen Jingfu;Han Zhifeng(Department of Vascular Surgery,Mingji Hospital Affiliated to Nanjing Medical University,Jiangsu,Nanjing 210000,China)

机构地区：[1]南京医科大学附属明基医院血管外科,南京210000

出　　处：《疑难病杂志》2025年第2期181-186,共6页Chinese Journal of Difficult and Complicated Cases

基　　金：江苏省卫生健康委科研课题项目(BJ20027)。

摘　　要：目的探讨血清脂质运载蛋白-2(Lipocalin-2)、纤维胶凝蛋白-2(Ficolin-2)与下肢动脉硬化闭塞症(LEASO)介入治疗后血管再狭窄的相关性。方法回顾性选取2018年1月—2023年6月南京医科大学附属明基医院血管外科行介入治疗的LEASO患者130例为LEASO组,根据随访1年是否发生血管再狭窄将LEASO患者分为再狭窄亚组40例和非再狭窄亚组90例;另选取同期医院健康体检者80例为健康对照组。采用酶联免疫吸附法检测血清Lipocalin-2、Ficolin-2水平;Pearson相关分析LEASO患者血清Lipocalin-2、Ficolin-2水平与管腔直径缩小率的相关性;多因素Logistic回归分析LEASO患者介入治疗后发生血管再狭窄的影响因素;受试者工作特征(ROC)曲线评价血清Lipocalin-2、Ficolin-2水平对LEASO患者介入治疗后发生血管再狭窄的预测效能。结果LEASO组血清Lipocalin-2、Ficolin-2水平高于健康对照组(t/P=23.943/<0.001、29.774/<0.001);LEASO患者血清Lipocalin-2、Ficolin-2水平与管腔直径缩小率呈正相关(r/P=0.719/<0.001、0.730/<0.001);介入治疗1年后,130例LEASO患者血管再狭窄发生率为30.77%(40/130)。再狭窄亚组糖尿病比例、高血压比例和血清Lipocalin-2、Ficolin-2水平高于非再狭窄亚组(χ^(2)/t/P=6.945/0.008、6.644/0.010、6.295/<0.001、5.657/<0.001);糖尿病、Lipocalin-2高、Ficolin-2高为LEASO患者介入治疗后发生血管再狭窄的独立危险因素[OR(95%CI)=3.383(1.187~9.647)、1.264(1.120~1.427)、1.272(1.113~1.454)];血清Lipocalin-2、Ficolin-2水平及二者联合预测LEASO患者介入治疗后血管再狭窄的AUC分别为0.789、0.786、0.875,二者联合预测的AUC大于单独预测的AUC(Z/P=2.502/0.012,2.339/0.019)。结论LEASO患者血清Lipocalin-2、Ficolin-2水平升高,与介入治疗后血管再狭窄密切相关,血清Lipocalin-2、Ficolin-2水平联合对LEASO介入治疗后血管再狭窄有较高的预测效能。Objective To investigate the correlation between serum Lipocalin-2,Ficolin-2,and vascular restenosis after interventional treatment of lower extremity arteriosclerosis obliterans(LEASO).Methods A total of 130 patients with LEASO who underwent interventional therapy in the Department of Vascular Surgery,Mingji Hospital Affiliated to Nanjing Medical University from January 2018 to June 2023 were selected as the LEASO group.According to whether vascular restenosis occurred during the 1-year follow-up,LEASO patients were divided into restenosis subgroup of 40 cases and non-restenosis subgroup of 90 cases.80 cases of healthy physical examination in the hospital during the same period were selected as healthy control group.The levels of serum Lipocalin-2 and Ficolin-2 were detected by enzyme-linked immunosorbent assay.Pearson correlation analysis was used to analyze the correlation between serum Lipocalin-2,Ficolin-2 levels and lumen diameter reduction rate in LEASO patients.Multivariate Logistic regression analysis was used to analyze the influencing factors of vascular restenosis after interventional therapy in LEASO patients.The receiver operating characteristic(ROC)curve was used to evaluate the predictive efficacy of serum Lipocalin-2 and Ficolin-2 levels on vascular restenosis after interventional therapy in LEASO patients.Results The serum levels of Lipocalin-2 and Ficolin-2 in the LEASO group were higher than those in the healthy control group,and the differences were statistically significant(t/P=23.943/<0.001,29.774/<0.001);Serum Lipocalin-2 and Ficolin-2 levels in LEASO patients were positively correlated with lumen diameter reduction rate(r/P=0.719/<0.001,0.730/<0.001);After 1 year of interventional therapy,the incidence of vascular restenosis in 130 patients with LEASO was 30.77%(40/130).The proportion of diabetes,hypertension and serum Lipocalin-2 and Ficolin-2 levels in the restenosis subgroup were higher than those in the non-restenosis subgroup,and the differences were statistically significant(χ^(2)/

关 键 词：下肢动脉硬化闭塞症 脂质运载蛋白-2 纤维胶凝蛋白-2 介入治疗 血管再狭窄 

分 类 号：R543.5[医药卫生—心血管疾病]